Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and tolerability of a drug called EBC-129, used alone and with pembrolizumab, in patients with advanced solid tumors. This open-label, phase 1ab study is divided into four parts to identify safe dosing levels and to explore the drugs effects in different patient groups. It aims to find the maximum tolerated dose and recommended phase 2 dose for EBC-129 alone and combined with pembrolizumab, targeting patients who have limited treatment options due to advanced cancer. The study includes four parts Part A tests escalating doses of EBC-129 alone to find safe dosing Part B tests escalating doses of EBC-129 combined with pembrolizumab Part C expands on Part A using the recommended dose of EBC-129 alone in more patients and Part D evaluates dosing schedules in patients with cancer types showing early responses. EBC-129 is given intravenously on Day 1 of each 21-day cycle in Parts A, B, and C, with varying dosing schedules in Part D. Pembrolizumab is administered every 21 days at a fixed dose. Participants will undergo monitoring for adverse events and treatment responses over several cycles, with assessments including tumor response rates and drug concentration measurements. The study tracks serious and treatment-emergent adverse events from before treatment until 30 days after the last dose, with outcome measures extending up to approximately 3.3 years. This includes evaluating tumor control, duration of response, progression, survival rates, and drug levels in the blood to understand the safety and effects of the treatments.
Actively Recruiting
Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of BGB-43395 combined with letrozole compared to a choice of approved cyclin-dependent kinase 46 inhibitors abemaciclib, palbociclib, or ribociclib combined with letrozole in adults with advanced or metastatic hormone receptor positive HR and human epidermal growth factor receptor 2 negative HER2- breast cancer. The study focuses on patients who have not previously received systemic treatment for advanced or metastatic disease. This phase 3 trial aims to provide insight into treatment options for this patient group. Participants are randomly assigned to one of two groups one receiving BGB-43395 plus letrozole, and the other receiving an investigators choice of CDK46 inhibitor abemaciclib, palbociclib, or ribociclib plus letrozole. All medications are taken orally. The study compares these treatment combinations over a period lasting up to approximately 4 years for primary outcomes, with longer follow-up for secondary outcomes. During the trial, participants will be regularly monitored for disease progression, response to treatment, overall survival, and safety through various assessments. These include evaluations of progression-free survival by independent review, overall response rate, duration of response, clinical benefit rate, and adverse events. Quality of life measures and other clinical outcomes are also tracked. Participant involvement may last up to 11 years to capture long-term effects and safety.
Actively Recruiting
This research aims to evaluate the effects of a six-week bright-light exposure combined with a specific exercise training program on patients with lung and esophageal cancer. The study focuses on improving sleep-wake rhythm, physical and mental symptoms, quality of life, and assessing one-year recurrence and survival rates. It is a randomized, double-blind clinical trial conducted at a single center in Taiwan involving participants with thoracic cancer. Participants are randomly assigned to one of two groups. The experimental group undergoes a rehabilitation program consisting of daily morning bright-light exposure for 36 minutes and tailored moderate-intensity walking sessions three times per week for six weeks, with weekly exercise consultations via a communication app. The control group participates in a six-week stretching exercise program involving four movements, lasting 10 minutes per session, three times a week. Both groups receive instruction through manuals, videos, and online resources. During the study, participants will be assessed five times before the intervention, at the 6th and 12th weeks, and at the 6th and 12th months. Researchers will measure sleep-wake rhythm changes, subjective and objective sleep quality, anxiety and depression levels, quality of life, and track cancer recurrence and survival rates. The study includes long-term follow-up to evaluate outcomes over one year.
Actively Recruiting
Researchers are studying limited-stage small cell lung cancer LS-SCLC patients to evaluate the safety and effectiveness of toripalimab alone or combined with tifcemalimab as follow-up consolidation therapy. This Phase 3, randomized, double-blind, placebo-controlled, multi-regional trial enrolls patients who have completed chemoradiotherapy without disease progression. Tifcemalimab targets B and T lymphocyte attenuator BTLA, while toripalimab targets the programmed death protein-1 PD-1, and neither drug is yet approved for this condition. Participants are randomly assigned to one of three groups one receiving tifcemalimab 200 mg IV plus toripalimab 240 mg IV every three weeks, another receiving toripalimab 240 mg IV with a placebo for tifcemalimab, and a third group receiving placebos for both drugs. The investigational treatments are administered intravenously as consolidation therapy after chemoradiotherapy. Treatment continues according to the study schedule, with follow-up assessments planned to monitor outcomes. Throughout the study, participants will undergo evaluations including overall survival and progression-free survival measurements for up to three and two years, respectively. Researchers will also assess response rates, disease control, duration of response, and safety through monitoring adverse events and laboratory tests. The study involves regular visits for treatment and assessments, with close monitoring to understand the effects of the therapies over time.
Actively Recruiting
Healthy Volunteer
Researchers are studying how vestibular problems and thinking abilities like attention and mental flexibility relate in older adults. The study focuses on how performing a balance task and a thinking task simultaneously affects their performance. Two groups will be compared healthy older adults and those who have experienced dizziness or falls in the past two years. The aim is to help design future assessment and training programs to reduce balance problems and falls in this population. Participants will complete questionnaires and simple cognitive tests while seated. They will then perform standing balance tasks on a portable force platform under various conditions, repeating some cognitive tasks simultaneously. Next, participants will walk on a treadmill wearing motion sensors, both with and without added thinking tasks such as serial subtraction and digit reordering. The total testing time is about 90 minutes. During the study, participants will be assessed with various measures including gait speed, stride length, step width, cadence, and trunk movement using wearable inertial sensors. Cognitive and balance confidence scales will also be used. The study includes a single baseline laboratory visit to collect these data. The results will help understand balance and cognitive function in older adults and inform future rehabilitation strategies.